Innovative regenerative medicines in the EU: a better future in evidence?
AffiliationCentre for Reviews and Dissemination, University of York, Heslington, York, YO10 5DD
MetadataShow full item record
AbstractDespite a steady stream of headlines suggesting they will transform the future of healthcare, high-tech regenerative medicines have, to date, been quite inaccessible to patients, with only eight having been granted an EU marketing licence in the last 7 years. Here, we outline some of the historical reasons for this paucity of licensed innovative regenerative medicines. We discuss the challenges to be overcome to expedite the development of this complex and rapidly changing area of medicine, together with possible reasons to be more optimistic for the future.
CitationInnovative regenerative medicines in the EU: a better future in evidence? 2017, 15(1):49 BMC Med
- The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
- Authors: Hettle R, Corbett M, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, Palmer S
- Issue date: 2017 Feb
- Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
- Authors: Lysaght T, Sugii S
- Issue date: 2016 Apr 7
- Translating cell-based regenerative medicines from research to successful products: challenges and solutions.
- Authors: Bayon Y, Vertès AA, Ronfard V, Egloff M, Snykers S, Salinas GF, Thomas R, Girling A, Lilford R, Clermont G, Kemp P
- Issue date: 2014 Aug
- Regenerative medicine: looking backward 10 years further on.
- Authors: Kemp P
- Issue date: 2016 Dec